{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T12:59:39Z","timestamp":1762001979715,"version":"build-2065373602"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,11]],"date-time":"2024-02-11T00:00:00Z","timestamp":1707609600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism Reports"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.ymgmr.2024.101064","type":"journal-article","created":{"date-parts":[[2024,2,19]],"date-time":"2024-02-19T23:24:40Z","timestamp":1708385080000},"page":"101064","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Real-world evidence study finds no new-onset diabetes or drug-related hyperglycemia in Pompe disease patients treated with avalglucosidase alfa"],"prefix":"10.1016","volume":"38","author":[{"given":"Alexandra","family":"Dumitriu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann","family":"Lucas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raffaella","family":"Colzani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgmr.2024.101064_bb0005","series-title":"The Online Metabolic and Molecular Bases of Inherited Disease","article-title":"Pompe disease: Glycogen storage disease type II, acid \u03b1-glucosidase (acid maltase) deficiency","author":"Reuser","year":"2018"},{"issue":"2","key":"10.1016\/j.ymgmr.2024.101064_bb0010","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/ajmg.a.35662","article-title":"How to describe the clinical spectrum in Pompe disease?","volume":"161A","author":"Gungor","year":"2013","journal-title":"Am. J. Med. Genet. A"},{"issue":"Pt 3","key":"10.1016\/j.ymgmr.2024.101064_bb0015","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/brain\/awh384","article-title":"Clinical manifestation and natural course of late-onset Pompe's disease in 54 Dutch patients","volume":"128","author":"Hagemans","year":"2005","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.ymgmr.2024.101064_bb0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ajmg.c.31324","article-title":"The new era of Pompe disease: advances in the detection, understanding of the phenotypic spectrum, pathophysiology, and management","volume":"160C","author":"Kishnani","year":"2012","journal-title":"Am. J. Med. Genet. C: Semin. Med. Genet."},{"issue":"9646","key":"10.1016\/j.ymgmr.2024.101064_bb0025","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/S0140-6736(08)61555-X","article-title":"Pompe's disease","volume":"372","author":"van der Ploeg","year":"2008","journal-title":"Lancet"},{"year":"2021","series-title":"NEXVIAZYME (Avalglucosidase Alfa-Ngpt) for Injection, for Intravenous Use. [Prescribing Information]","key":"10.1016\/j.ymgmr.2024.101064_bb0030"},{"year":"2022","series-title":"NEXVIADYME Avalglucosidase Alfa 100 Mg Powder for Concentrate for Solution for Infusion. [Summary of Product Characteristics]","key":"10.1016\/j.ymgmr.2024.101064_bb0035"},{"issue":"4","key":"10.1016\/j.ymgmr.2024.101064_bb0040","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.bbamcr.2008.10.016","article-title":"Sorting of lysosomal proteins","volume":"1793","author":"Braulke","year":"2009","journal-title":"Biochim. Biophys. Acta"},{"issue":"3","key":"10.1016\/j.ymgmr.2024.101064_bb0045","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1016\/S0021-9258(18)53985-5","article-title":"Structural and functional changes of lysosomal acid alpha-glucosidase during intracellular transport and maturation","volume":"268","author":"Wisselaar","year":"1993","journal-title":"J. Biol. Chem."},{"year":"2014","series-title":"MYOZYME (alglucosidase alfa) Injectable for Intravenous Infusion. [Prescribing Information]","key":"10.1016\/j.ymgmr.2024.101064_bb0050"},{"year":"2014","series-title":"LUMIZYME (Alglucosidase Alfa) for Injection, for Intravenous Use. [Prescribing Information]","key":"10.1016\/j.ymgmr.2024.101064_bb0055"},{"issue":"12","key":"10.1016\/j.ymgmr.2024.101064_bb0060","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1021\/bc400365a","article-title":"Glycan structure determinants for cation-independent mannose 6-phosphate receptor binding and cellular uptake of a recombinant protein","volume":"24","author":"Zhou","year":"2013","journal-title":"Bioconjug. Chem."},{"issue":"6","key":"10.1016\/j.ymgmr.2024.101064_bb0065","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/mt.2009.37","article-title":"Glycoengineered acid alpha-glucosidase with improved efficacy at correcting the metabolic aberrations and motor function deficits in a mouse model of Pompe disease","volume":"17","author":"Zhu","year":"2009","journal-title":"Mol. Ther."},{"author":"Centers for Disease Control and Prevention","key":"10.1016\/j.ymgmr.2024.101064_bb0070"},{"year":"2020","series-title":"Dietary Guidelines for Americans, 2020-2025","author":"U.S. Department of Agriculture and U.S. Department of Health and Human Services","key":"10.1016\/j.ymgmr.2024.101064_bb0075"},{"issue":"5","key":"10.1016\/j.ymgmr.2024.101064_bb0080","doi-asserted-by":"crossref","first-page":"731","DOI":"10.2337\/dci19-0014","article-title":"Nutrition therapy for adults with diabetes or prediabetes: a consensus report","volume":"42","author":"Evert","year":"2019","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.ymgmr.2024.101064_bb0085","doi-asserted-by":"crossref","DOI":"10.1002\/edm2.411","article-title":"Simplifying carb counting: a randomized controlled study - feasibility and efficacy of an individualized, simple, patient-centred carb counting tool","volume":"6","author":"Witkow","year":"2023","journal-title":"Endocrinol. Diabet. Metab."},{"issue":"12","key":"10.1016\/j.ymgmr.2024.101064_bb0090","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/S1474-4422(21)00241-6","article-title":"Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial","volume":"20","author":"Diaz-Manera","year":"2021","journal-title":"Lancet Neurol."},{"issue":"5","key":"10.1016\/j.ymgmr.2024.101064_bb0095","doi-asserted-by":"crossref","first-page":"e536","DOI":"10.1212\/WNL.0000000000200746","article-title":"Long-term safety and efficacy of avalglucosidase alfa in patients with late-onset Pompe disease","volume":"99","author":"Dimachkie","year":"2022","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.ymgmr.2024.101064_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.gim.2022.10.010","article-title":"Safety and efficacy of avalglucosidase alfa in individuals with infantile-onset Pompe disease enrolled in the phase 2, open-label Mini-COMET study: the 6-month primary analysis report","volume":"25","author":"Kishnani","year":"2023","journal-title":"Genet. Med."},{"issue":"3","key":"10.1016\/j.ymgmr.2024.101064_bb0105","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.nmd.2018.12.004","volume":"29","author":"Pena","year":"2019","journal-title":"Neuromuscul. Disord."},{"issue":"6","key":"10.1016\/j.ymgmr.2024.101064_bb0110","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1001\/jamaneurol.2023.0552","article-title":"Efficacy and safety of Avalglucosidase alfa in patients with late-onset Pompe disease after 97 weeks: a phase 3 randomized clinical trial","volume":"80","author":"Kishnani","year":"2023","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.ymgmr.2024.101064_bb0115","doi-asserted-by":"crossref","first-page":"S348","DOI":"10.1016\/j.gim.2022.01.566","article-title":"Mini-COMET: Safety and efficacy of \u226597 weeks\u2019 avalglucosidase alfa in infantile-onset Pompe disease participants previously treated with alglucosidase alfa","volume":"24","author":"Kronn","year":"2022","journal-title":"Genet. Med."},{"issue":"5","key":"10.1016\/j.ymgmr.2024.101064_bb0120","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1097\/MPA.0000000000001318","article-title":"Glucose counter-regulation after acute pancreatitis","volume":"48","author":"Bharmal","year":"2019","journal-title":"Pancreas"},{"issue":"5","key":"10.1016\/j.ymgmr.2024.101064_bb0125","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1007\/s10620-021-06982-8","article-title":"Stress hyperglycemia is independently associated with persistent organ failure in acute pancreatitis","volume":"67","author":"Yang","year":"2022","journal-title":"Dig. Dis. Sci."}],"container-title":["Molecular Genetics and Metabolism Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221442692400017X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221442692400017X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T12:54:21Z","timestamp":1762001661000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221442692400017X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":25,"alternative-id":["S221442692400017X"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgmr.2024.101064","relation":{},"ISSN":["2214-4269"],"issn-type":[{"type":"print","value":"2214-4269"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world evidence study finds no new-onset diabetes or drug-related hyperglycemia in Pompe disease patients treated with avalglucosidase alfa","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgmr.2024.101064","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101064"}}